chiara zocchi

Dr. chiara zocchi

Careggi University Hospital

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
AAAlessia Argirò
Alessia Argirò
MZmattia zampieri
mattia zampieri
MBMartina Berteotti
Martina Berteotti
AMAlberto Marchi
Alberto Marchi
LTLuigi Tassetti
Luigi Tassetti
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto
Hypertrophic cardiomyopathy (HCM) is a common myocardial disease characterized by otherwise unexplained left ventricular hypertrophy. The main cause of disabling symptoms in patients with HCM is left ventricular outflow tract (LVOT) obstruction. This phenomenon is multifactorial, determined both by anatomical and functional abnormalities: myocardial hypercontractility is believed to represent one of its major determinants. The anatomical anomalies are targeted by surgical interventions, whereas attenuating hypercontractility is the objective of old and new drugs including the novel class of allosteric myosin inhibitors. This review summarizes the current treatment modalities and discusses the emerging therapeutical opportunities focusing on the recently developed cardiac myosin ATPase inhibitors Mavacamten and CK-274. Novel surgical and interventional approaches are also discussed.

1 December 2021 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
LTLuigi Tassetti
Luigi Tassetti
FGFrancesca Girolami
Francesca Girolami
CFCarlo Fumagalli
Carlo Fumagalli
AAAlessia Argirò
Alessia Argirò
GRGiuseppe Ricciardi
Giuseppe Ricciardi
Iacopo OlivottoIacopo Olivotto
Iacopo Olivotto

14 December 2023 in Diagnostics
Verified
Journal Article
Open access
PDF file
MZmattia zampieri
mattia zampieri
CFChiara Di Filippo
Chiara Di Filippo
chiara zocchichiara zocchi
chiara zocchi
VFVera Fico
Vera Fico
CGCristina Golinelli
Cristina Golinelli
SFSilvia Favilli
Silvia Favilli
Restrictive cardiomyopathy (RCM) is characterized by restrictive ventricular pathophysiology determined by increased myocardial stiffness. While suspicion of RCM is initially raised by clinical evaluation and supported by electrocardiographic and echocardiographic findings, invasive hemodynamic evaluation is often required for diagnosis and management of patients during follow-up. RCM is commonly associated with a poor prognosis and a high incidence of heart failure, and PH is reported in paediatric patients with RCM. Currently, only a few therapies are available for specific RCM aetiologies. Early referral to centres for advanced heart failure treatment is often necessary. The aim of this review is to address questions frequently asked when facing paediatric patients with RCM, including issues related to aetiologies, clinical presentation, diagnostic process and prognosis.

13 June 2025 in Cardiogenetics
Verified
Journal Article
Open access
PDF file
Michele CiabattiMichele Ciabatti
Michele Ciabatti
PNPasquale Notarstefano
Pasquale Notarstefano
chiara zocchichiara zocchi
chiara zocchi
GVGiacomo Virgili
Giacomo Virgili
FBFulvio Bellocci
Fulvio Bellocci
MPMaurizio Pieroni
Maurizio Pieroni
Brugada syndrome (BrS) has been traditionally considered a pure electrical disorder without an underlying structural substrate. However, early ECG studies showed the presence of depolarization abnormalities in this condition, while many studies based on advanced imaging have suggested the presence of subtle structural alterations. On the other hand, electrophysiological study (EPS) and electroanatomic mapping (EAM) techniques have provided important data regarding right ventricular functional and structural arrhythmic substrate. More recently, histology and immunology shed light on the possible role of fibrotic and inflammatory substrates in BrS. Notably, a significant overlap between electro anatomical and structural features in BrS and arrhythmogenic cardiomyopathy has been proposed. In this review, we summarized the physio pathological pathways and substrate underlying BrS. A deeper knowledge of the structural abnormalities involved in the pathogenesis of this disease could improve our diagnostic and prognostic approach, while novel findings regarding the role of inflammation and immune activation could potentially lead to new therapeutic strategies for BrS.